XBiotech Inc.
XBITHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeXBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. The company carries a $67.1M market cap, placing it firmly in the micro-cap category. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Market Cap
$67.1M
Beta
0.85
P/E (TTM)
—
P/E (Fwd)
16.92
EPS (TTM)
$-1.48
EPS (Fwd)
$0.13
ROE
-29.9%
ROA
-19.3%
Cash
$109.5M
Total Debt
$0
Free CF
-$28.5M
52W Change
-19.7%
Annual Financials
Cash vs Debt
Where XBIT stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, XBIT finished 5.93% below its 150-day moving average ($2.36) and 7.11% below its 200-day moving average ($2.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XBIT overbought or oversold?
At the September 2, 2026 close, XBIT's RSI(14) was 25.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
XBiotech Inc. reports $109.5M in cash and $0 in total debt. Free cash flow is running at -$28.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -29.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $4.0M (2022) to $0 (2025), a 100% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence XBiotech Inc.'s trajectory.